AXGN · Axogen
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $42.50
Note written ·
Price against the kill line
31.6% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $42.50, on record since 11 November 2026. The shares are up 13.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $42.50, the price of Axogen's September 2026 public offering, which would erase every gain since that sale. 2026 revenue excluding BioCircuit under $283 million, or full-year 2026 gross margin under 73%, would also show the case failing.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 28 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 75.8
- Revenue, change on a year (%)
- +26.2
- Gross margin (%)
- 74.8
- Operating margin (%)
- 1.3
- Free cash flow, four quarters ($M)
- 22.0
- Free-cash-flow yield (%)
- 0.7
All filed numbers
What Axogen reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 75.8 | +26.2 | 74.8 | 1.3 |
| first filed | 69.7 | +23.1 | 72.7 | −3.1 |
| first filed | 61.5 | +26.6 | 75.2 | −4.6 |
| first filed | 59.9 | +21.3 | 74.1 | −16.3 |
| first filed | 60.1 | +23.5 | 76.6 | 3.2 |
| first filed | 56.7 | +18.3 | 74.2 | 3.0 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −31.9 | 2.3 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +25.3 |
| Operating cash flow ($M) | 28.4 |
| Capital spending ($M) | 6.3 |
| Free cash flow ($M) | 22.0 |
| Cash and short-term investments ($M) | 348 |
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 34.0 |
| Inventory ($M) | 49.1 |
| Shareholders' equity ($M) | 496 |
| Market value ($M) | 3,341 |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 6.7 |
| Free-cash-flow yield (%) | 0.7 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 8.6% of shares outstanding sold short, 3.0 days of average trading to cover, +9.1% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $174K |
| 12 monthsfrom | $0 | $17.1M |
The thesis
Axogen's nerve-repair revenue grew 26.2% in the third quarter of 2026, and prostate surgery adds a market the company sizes at $754 million that sits outside its guidance. On that evidence the shares are modestly more likely than not to beat the S&P 500 over the next three months. The fourth-quarter 2026 report settles the case: it shows whether revenue excluding the BioCircuit acquisition reaches the at least $283 million guided for 2026, and whether gross margin holds at 73% or better.
The shares closed at $58.63 on 11 November 2026, up from $50.89 the session before, and touched a 52-week intraday high of $59.72 that day. No company filing, press release or analyst rating change explaining the move appeared on 11 November 2026. Management spoke at the Canaccord Genuity MedTech forum that morning and gave no new financial figures, per Investing.com's account of the session.
The rating is Medium because the business evidence is intact and the price now carries more of it. The 11 November 2026 close sits above MarketBeat's consensus target of $57.92. Further gains need new figures, and the next scheduled ones arrive with the fourth-quarter report.
Bullish and bearish views on Axogen, Inc.
The bull case on Axogen, Inc. (AXGN), in brief: growth is broad and organic. The bear case: the price has passed the consensus target.
Bull case
- Growth is broad and organic. Third-quarter revenue rose 26.2% to $75.8 million from $60.1 million, before BioCircuit closed on 1 October 2026. Nine-month revenue reached $207.0 million against $165.3 million a year earlier (Form 8-K, 28 October 2026).
- The coverage gap has nearly closed. Positive decisions from Elevance and Aetna took commercial coverage for Avance to about 96% of US covered lives (Form 8-K, 28 October 2026).
- Prostate is outside current guidance. The 9 November 2026 presentation reported more than 220 patients reconstructed with Avance, 117 with at least six months of follow-up. Management said on 28 October 2026 that the opportunity is in neither current nor long-range guidance, per MarketBeat's call summary.
- BioCircuit gets the full sales force. At the 11 November 2026 Canaccord forum, management said it is moving the NerveTape product from about 400 accounts toward the more than 3,000 Axogen already serves, using its direct sales team (Investing.com, 11 November 2026).
- Cash generation has turned positive. Free cash flow was $18.9 million for the nine months to 30 September 2026, against negative $5.9 million a year earlier. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin rose to 17.7% in the third quarter from 15.4% (Form 8-K, 28 October 2026).
- The balance sheet funds expansion. Cash, cash equivalents, restricted cash and investments stood at $350.1 million on 30 September 2026, per MarketBeat's call summary, before the $200 million BioCircuit payment on 1 October 2026.
Bear case
- The price has passed the consensus target. The $58.63 close on 11 November 2026 is above MarketBeat's $57.92 consensus target and just under the $60 targets Canaccord Genuity, Barclays and Truist set on 29 October 2026.
- Valuation leaves little room. TIKR estimated roughly 83 times forward earnings after the 28 October 2026 jump, and the shares have risen since. That multiple rests on growth staying above 25%.
- Prostate revenue is years away. Management said on 11 November 2026 that a 2027 pilot in 10 territories will test the commercial model before any decision to scale, and that Axogen has not yet engaged payers on prostate coverage (Investing.com).
- The prostate evidence is uncontrolled. The 9 November 2026 outcome figures come from the company's own clinical experience sites without a comparison group.
- Gross margin is moving down. Third-quarter gross margin fell to 74.8% from 76.6%, which the 10-Q attributes mainly to higher product costs. Guidance of at least 73% for 2026 allows further decline.
- Share issuance has followed strength. Axogen sold 4,600,000 shares at $31.00 in January 2026 and 5,646,500 shares in September 2026 for net proceeds of $225.0 million, per the third-quarter 10-Q.
Price setup
The close of $58.63 on 11 November 2026 is 1.8% below that day's 52-week intraday high of $59.72. The shares had spent 4 November to 10 November 2026 between $48.75 and $51.35 before the 11 November 2026 jump. MarketBeat reported them at $53.73 at midday on 11 November 2026, so most of the day's gain came in the afternoon, with no reported cause.
The 50-day moving average is $42.95 and the 200-day is $40.31 as of 11 November 2026, both far below the last close. The three-month change is 22.0%, measured from $48.05 on 13 August 2026. The 52-week closing low is $23.55 on 14 November 2025. The September 2026 offering price is the nearest level with a public meaning: the price at which 5,646,500 new shares were placed.
Catalysts ahead
- 17 November 2026: Jefferies Global Healthcare Conference fireside chat in London, 8:30 AM ET. Management may comment on BioCircuit integration and fourth-quarter trends after the shares' 11 November 2026 jump.
- 2 December 2026: Piper Sandler 38th Annual Healthcare Conference presentation, 8:00 AM ET. It is the last scheduled management appearance before the fourth-quarter report.
- ~25 February 2027 (est.): Fourth-quarter and full-year 2026 report. It settles whether revenue excluding BioCircuit reaches at least $283 million, gross margin holds at 73% or better and BioCircuit delivers at least $7 million.
- ~March 2027 (est.): Axogen investor day. Management said it would give the financial and commercial plan for prostate market development there, which sets how much spending comes before revenue.
What would change the view
A daily close below $42.50, the price of Axogen's September 2026 public offering, which would erase every gain since that sale. 2026 revenue excluding BioCircuit under $283 million, or full-year 2026 gross margin under 73%, would also show the case failing.
The risks this note tracks, each with what would confirm it:
- A high multiple compresses if growth slows from the 26.2% reported for the third quarter. Confirmed by: 2026 revenue excluding BioCircuit below the at least $283 million guided on 28 October 2026.
- Higher product costs keep pushing gross margin down from the 74.8% reported for the third quarter. Confirmed by: full-year 2026 gross margin below the at least 73% guidance.
- BioCircuit fails to justify its $200 million cash price. Confirmed by: fourth-quarter BioCircuit revenue below the at least $7 million included in 2026 guidance.
- Confirmatory studies fail to verify Avance's clinical benefit, putting its continued approval in question. Confirmed by: an adverse study result or Food and Drug Administration action on the Avance license.
- Uncontrolled prostate outcome data fail to hold up in larger or comparative studies, slowing surgeon adoption and payer coverage. Confirmed by: published or presented prostate results showing lower functional recovery than the figures cited on 9 November 2026, or payers declining to cover the indication.
- Prostate market development raises spending ahead of revenue. Confirmed by: investor-day plans that lead to adjusted EBITDA margin falling below the third quarter's 17.7%.
What it trades with
Axogen is grouped with Enovis (ENOV), Vericel (VCEL), OrthoPediatrics (KIDS) and Glaukos (GKOS) in medtech. Its moves since 28 October 2026 have followed its own news: the third-quarter report, the 9 November 2026 prostate call and the 11 November 2026 forum. Revenue is almost entirely domestic, with US sales of $75.054 million of $75.834 million in the third quarter, so currency and foreign demand barely touch the result. A broad sell-off in high-multiple small and mid-cap growth stocks would be the main outside pressure.
The evidence, claim by claim (8)
- Third-quarter revenue was $75.8 million, up 26.2% from $60.1 million a year earlier. Axogen Form 8-K earnings release, 28 October 2026 · as of
- 2026 revenue guidance rose to at least $290 million, including at least $7 million from BioCircuit and at least $283 million excluding it. Axogen Form 8-K earnings release, 28 October 2026 · as of
- Third-quarter gross margin was 74.8%, down from 76.6%, mainly because of higher product costs; 2026 gross margin guidance is at least 73%. Axogen Q3 2026 Form 10-Q and Form 8-K earnings release · as of
- Commercial payer coverage for Avance reached about 96% of US covered lives after positive decisions from Elevance and Aetna. Axogen Form 8-K earnings release, 28 October 2026 · as of
- Axogen sized the US prostate nerve reconstruction market at $754 million and reported more than 220 patients reconstructed with Avance, 117 with at least six months of follow-up. Axogen prostate nerve reconstruction investor presentation · as of
- Management plans a 2027 prostate pilot in 10 territories before deciding whether to scale, and has not yet engaged payers on prostate coverage. Canaccord Genuity MedTech forum fireside chat, per Investing.com · as of
- Cash, equivalents, restricted cash and investments were $350.1 million at 30 September 2026; management said prostate is not in current or long-range guidance. MarketBeat summary of Q3 2026 earnings call · as of
- Canaccord Genuity, Barclays and Truist raised price targets to $60 on 29 October 2026; MarketBeat's consensus target was $57.92 on 11 November 2026. Benzinga analyst items; MarketBeat 11 November 2026 · as of
Sources
- AxoGen at Canaccord forum: growth plan widens beyond nerve repair · uk.investing.com ·
- AxoGen (NASDAQ:AXGN) Hits New 1-Year High - What's Next? · marketbeat.com ·
- Axogen, Inc. - Form 8-K - FY2026 · sec.gov
- Axogen, Inc. - Form 10-Q - FY2026 · sec.gov
- Prostate Nerve Reconstruction Investor Event November 9, 2026 · d1io3yog0oux5.cloudfront.net ·
- MarketBeat ·
- Axogen ·
- Axogen Soars 29% on Q3 Beat, Lifts 2026 Revenue Guidance to at Least $290 Million · tikr.com
Related · shared themes
ADPT
Adaptive Biotechnologies
Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter…
CSTL
Castle Biosciences
Castle Biosciences raised 2026 revenue guidance to $385–395 million and held its 50–52% TissueCypher volume growth plan; the fourth-quarter…
DXCM
DexCom
Dexcom's raised 2026 outlook and 25.3% third-quarter operating margin give the shares a modest edge after a diabetes-device sell-off erased…
GKOS
Glaukos
Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million, giving the shares…
See also · stocks to watch